Your session is about to expire
← Back to Search
CAR T-cell Therapy
MT-101 for T-Cell Lymphoma (IMAGINE Trial)
Phase 1 & 2
Waitlist Available
Research Sponsored by Myeloid Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new treatment called MT-101 for patients with T cell Lymphoma. MT-101 is made from the patient's own blood cells, which are changed to attack cancer cells. The study will check if the treatment is safe and effective.
Eligible Conditions
- Cell Therapy
- Peripheral T-Cell Lymphoma
- Cutaneous T-Cell Lymphoma
- Mycosis Fungoides and Sezary Syndrome
- Mycosis Fungoides
- Adoptive Cell Therapy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and Tolerability of MT-101
Secondary study objectives
MT-101 cell kinetics in blood
The objective response rate
Other study objectives
Duration of response (DOR)
Overall survival (OS)
Progression free survival (PFS)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Cohort 2 and Cohort 4Experimental Treatment1 Intervention
MT-101 preceded by conditioning (lymphodepleting) chemotherapy
Group II: Cohort 1 and Cohort 3Experimental Treatment1 Intervention
MT-101
Find a Location
Who is running the clinical trial?
Myeloid TherapeuticsLead Sponsor
2 Previous Clinical Trials
96 Total Patients Enrolled
Michele Gerber, MD, MPHStudy DirectorMyeloid Therapeutics
1 Previous Clinical Trials
48 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have experienced a severe allergic reaction to penicillin in the past.You have a specific stage of a condition called myelofibrosis, which is categorized as B1 or B2 as explained in the study's instructions.The cancer has spread to the central nervous system.You have had bad reactions or intolerance to leukapheresis, plasmapheresis, or donating blood in the past.You have any sudden illness, like a fever, except if the fever is caused by your tumor.You have received a transplant using someone else's cells in the past.You have had other types of cancer before, but they have been treated or are in complete remission.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort 2 and Cohort 4
- Group 2: Cohort 1 and Cohort 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger